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Abstract: Platinum-based chemotherapy is the main type of I-line treatment of advanced and non-operative
NSCLC patients without EGFR gene mutation. The excision repair cross-complementation group 1 (ERCC1) is
an enzyme that executes the incision of the damaged DNA strand and removes platinum-induced DNA adducts.
We investigated whether ERCC1 gene polymorphism has an effect on the response to chemotherapy and surviv-
al in 43 patients with NSCLC treated with platinum-based chemotherapy. ERCC1 19007 T>C SNPs were as-
sessed using a PCR-RFLP methods in DNA isolated from peripheral blood lymphocytes. Disease control oc-
curred significantly (p = 0.045) more frequently in patients with CC or CT genotype compared to patients with
TT genotype. Median PFS and OS for CC homozygous were 4 and 10.5 months, 4 and 12.5 months for CT
heterozygous, but only 0.3 and 1.5 months for TT homozygous patients, respectively. The probability of PFS was
significantly higher (HR = 0.438, 95% CI: 0.084–0.881, p = 0.03) and probability of OS was insignificantly
higher (HR = 0.503, 95% CI: 0.129–1.137, p = 0.084) in patients with CC or CT genotype than in patients with
TT genotype. Uncommon TT genotype of ERCC1 19007 T>C polymorphism could predict poor response and
shortening of progression free survival in NSCLC patients treated with platinum-based I-line chemotherapy.
The analysis of this polymorphism may serve as a promising tool in the qualification of advanced NSCLC pa-
tients for appropriate chemotherapy. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 1, 80–86)
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Introduction
Lung cancer is the commonest malignancy in the
world. 20,000 people die each year in Poland because
of this cancer. Non-small cell lung cancer (NSCLC)
represents over 85% of lung cancer cases. Surgical
resection is possible in the early stages of NSCLC. In
Poland, only about 15–20% of newly diagnosed
NSCLC cases could be qualified for operation. There-
fore, chemotherapy and radiotherapy play the domi-
nant roles in the multidisciplinary treatment of pa-
tients with advanced NSCLC [1].
Chemotherapy based on platinum compounds and
third generation drugs is currently the main type of
I-line treatment of advanced, non-operative non-small
cell lung cancer (NSCLC) in patients without EGFR
gene mutation. Unfortunately, objective response to
chemotherapy is achieved in less than 40% of patients
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and median overall survival of treated patients does
not exceed eight months [2].
The mechanism of action of many cytotoxic drugs
(platinum compounds, gemcitabine) is based on the
disruption of genetic material integrity. The destruc-
tion of cells by platinum compounds requires bind-
ing of the drug to DNA and the creation of platinum-
DNA adducts, thereby inhibiting DNA replication.
Therefore, one of the basic mechanisms of resistance
to therapy is increased or deregulated DNA repara-
tion. Nucleotide excision repair (NER) complex has
a central role in DNA repair. The excision repair
cross-complementation group 1 (ERCC1) with xero-
derma pigmentosum-F (XPF), enzymes that belong
to NER complex, execute the incision of the dam-
aged DNA strand and remove cisplatin-induced DNA
adducts [3].
Expression of ERCC1 protein by the tumor cells
could predict response and survival benefit from plat-
inum-based adjuvant and I-line chemotherapy in non-
small cell lung cancer [4, 5]. 19007 T>C (N118N,
rs11615) and 8092 C>A (Q504K, rs3212986) poly-
morphisms of ERCC1 gene could change ERCC1
mRNA expression, ERCC1 protein expression or
ERCC1 enzyme function [6, 7]. However, other au-
thors have suggested that these polymorphisms are
not related to phenotypic differences in the ERCC1
protein, but rather may be linked to other causative
variants or haplotypes [8]. Nevertheless, this data lets
us hypothesize that differences in response to che-
motherapy could be related to single nucleotide poly-
morphisms (SNPs) in genes encoding proteins which
play a key role in DNA repair. Therefore, in this re-
port, we analyzed the significance of the ERCC1 gene
19007 T>C polymorphism as a predictive and prog-
nostic marker in NSCLC patients treated with plati-
num-based I-line chemotherapy.
Material and methods
Study population. The study population consisted of 43
pathologically verified non-small cell lung cancer patients.
Patients were staged as locally advanced (stage IIIB) or
advanced (metastatic, stage IV) disease using computed
tomography and other available methods. Detailed medi-
cal history about each patient was collected. The clinical
characteristics of lung cancer patients are presented in Ta-
ble 1. Patients received platinum-based first-line chemother-
apy. All cases were treated in the Department of Pneu-
monology, Oncology and Allergology of the Medical Uni-
versity of Lublin. Response to chemotherapy was evaluated
according to the RECIST criteria. The results of ERCC1
genotyping were correlated with response to treatment, pro-
gression free survival and overall survival of examined pa-
tients.
Before the investigation, the agreement of the Ethical
Committee of the Medical University of Lublin was obtained.
From each patient, venous blood was collected and ge-
nomic DNA was extracted using Qiagen Blood Mini Kit
(Qiagen, Germany).
ERCC1 genotyping. The ERCC1 19007 T>C genotypes
were detected using the PCR-based restriction frag-
ment length polymorphism (PCR-RFLP) method as
previously described. The primers were: forward primer:
5’-AGGACCACAGGACACGCAGA-3’ and reverse primer:
5’-CATAGAACAGTCCAGAACAC-3’, which produced
a 525 bp fragment. PCR reaction was performed in a to-
tal volume of 25 μl containing 100 ng of template DNA,
1 μM of each primer, 0.2 mM of each dNTP, 2.4 mM
MgCl2 and 1.0 U Taq polymerase with 1 × reaction buff-
er (Fermentas, Canada). PCR amplification was carried
out in a T Personal (Biometra, Germany) thermocycler
in the following conditions: initial denaturation at 96°C
for 5 min, followed by 35 cycles of 30 sec. at 94°C, 30 sec.
at 61°C and 1.0 min. at 72°C and a final elongation step
of 10 min. at 72°C. PCR products were digested over-
night with 5 U of BsrDI enzyme (Fermentas, Canada).
The three possible genotypes were defined by three dis-
tinct banding patterns: homozygous of TT genotype cor-
responded to 368- and 157-bp fragments, heterozygous
of CT genotype corresponded to 525-, 368- and 157-bp
fragments, and finally homozygous of CC genotype cor-
responded to an undigested band of 525bp (Figure 1).
The restricted products were analyzed by electrophore-
sis in 2% agarose gel containing ethidium bromide.
Statistical analysis. Chi-square test was used to compare
the characteristics of the patient groups divided according
to ERCC1 19007 T>C polymorphism. The U-Mann–Whit-
ney test and Kruskal–Wallis ANOVA median test were used
for testing equality of population medians among groups.
Kaplan–Meier method was used for the comparison of sur-
vival probability between the groups of different ERCC1
genotypes. Finally, the Cox regression model with stepwise
selection procedures by minimum AIC was used to estab-
lish factors affecting patient survival.
Figure 1. Representative analysis of ERCC1 1907 T>C
polymorphism (lanes: 7, 13, 15 — CC homozygotes, lanes:
4, 6, 9, 10, 12, 14 — CT heterozygotes, lanes: 1, 2, 3, 5, 8 11
— TT homozygotes, M — DNA ladder)
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Results
Patient characteristics and frequencies
of ERCC1 genotypes
Baseline characteristics and frequencies of ERCC1
genotypes in the group of 43 NSCLC patients (me-
dian age 63 years) are shown in Table 1. 76.7% of
the patients were male. The pack-years value was
calculated as the number of cigarette packs smoked
per day multiplied by the number of years. Median
pack-years value was 48. Very good performance
status (ECOG PS = 0) accounted for 58.1% of pa-
tients. Squamous-cell carcinoma was diagnosed in
58.1% of patients, adenocarcinoma in 25.6% and
other histological types in 16.3% of patients. 53.5%
of patients had locally advanced NSCLC (stage
IIIB). The median number of platinum-based che-
motherapy cycles was four (range: 1–6). Platinum
(cisplatin or carboplatin) was combined with vi-
norelbine in 30 patients (69.8%), gemcitabine in
seven patients (16.3%), paclitaxel in three patients
(6.95%), and with etoposid in three patients
(6.95%). Sequential radiation therapy was admin-
istered in nine patients (20.9%).
CC homozygous variant of the ERCC1 19007
T>C polymorphism was presented in 11 patients
(25.6%), heterozygous variant in 25 patients
(58.1%), and TT heterozygous variant in seven pa-
tients (16.3%). The distribution of polymorphic vari-
ants of ERCC1 gene did not depend on age, gender,
histological type, clinical stage of disease, chemo-
therapy regimen, smoking, or performance status of
NSCLC patients (Table 1).
ERCC1 19007 T>C polymorphism
and chemotherapeutic response
Complete remission was observed in five patients
(11.6%), and partial response in 14 patients (32.6%).
In the non-responders’ group, stable disease was ob-
served in five patients (11.6%) and progressive dis-
ease in 19 patients (44.2%). Disease control (CR, PR
Table 1A. Characteristics of NSCLC patients and ERCC1 genotype distribution
Factors All patients (n=43) ERCC1 19007 T>C polymorphism  p and c2 value
CC CT TT
(n = 11, 25.6%) (n = 25, 58.1%) (n = 7, 16.3%)
Age (median) 63 years 63 years 60 years 68 years 0.582
1.083
Gender
Male 33 (76.7%) 10 (90.9%) 19 (76%) 4 (57%) 0.253
Female 10 (23.3%) 1 (9.1%) 6 (24%) 3 (43%) 2.751
Pack-years (median) 48 53 44 40 0.178
3.45
WHO performance status
0 25 (58.1%) 7 (63.6%) 16 (64%) 2 (28.6%) 0.223
1 or 2 18 (41.0%) 4 (36.4%) 9 (36%) 5 (71.4%) 3.0
Weight loss
Non (< 5%) 20 (46.5%) 3 (27.3%) 15 (60%) 2 (28.6%) 0.112
Yes (≥ 5%) 23 (53.5%) 8 (72.7%) 10 (40%) 5 (71.4%) 4.37
Histological type
Squamous cell carcinoma 25 (58.1%) 8 (72.7%) 11 (44%) 6 (85.7%) 0.266
Adenocarcinoma 11 (25.6%) 3 (27.3%) 7 (28%) 1 (14.3%) 7.636
Giant cell carcinoma 5 (11.6%) 0 (0%) 5 (20%) 0 (0%)
NOS 2 (4.7%) 0 (0%) 2 (8%) 0 (0%)
TNM stage
Locally advanced 23 (53.5%) 7 (63.6%) 14 (56%) 2 (28.6%) 0.322
Advanced 20 (46.5%) 4 (36.4%) 11 (44%) 5 (71.4%) 2.266
Median number of chemotherapy cycles 4 4 4 2 0.674
0.789
Median PFS (months) 4 4 4 0.3 0.116
4.31
Median OS (months) 10.5 10.5 12.5 1.5 0.203
3.188
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and SD) occurred in 24 patients (55.8%). The medi-
an progression-free survival (MPFS) was four months
for the whole group of patients and 16.5 months for
responding patients (Tables 1, 2).
The carriers of TT genotype showed disease pro-
gression slightly (p = 0.052) more frequently than
carriers of allele C (CC and CT genotype). Disease
control occurred significantly (p = 0.045) more fre-
quently in patients with CC or CT genotype compared
to patients with TT genotype (Table 2).
Median progression free survival was 4 months for
CC homozygous and CT heterozygous patients, but
only 0.3 months for TT homozygous patients (Table 1).
In Kaplan–Meier analysis, the probability of progres-
sion free survival was significantly higher
(HR = 0.438, p = 0.03) in patients with CC or CT gen-
otype than in patients with TT genotype (Figure 2).
ERCC1 19007 C>T polymorphism
and overall survival
Median survival time (MST) was 10.5 months for all
NSCLC patients, 10.5 months for carriers of CC gen-
otype, 12.5 months for patients with CT genotype, but
only 1.5 months for TT homozygous patients (Table 1).
Patients with CC or CT genotype showed insignifi-
cantly (p = 0.084) higher probability of survival than
those with TT genotype. The percentage of patients
with survival longer than one year was insignificantly
higher (p = 0.531) in the group of patients with CC
or CT genotypes compared to the group of patients
with TT genotype (Figure 3).
In Cox proportional hazard regression model, poor
performance status (HR = 16.48, 95% CI: 4.48–60.65,
p < 0.0001), squamous-cell carcinoma diagnosis
(HR = 3.26, 95% CI: 1.38–7.74, p = 0.0075) and ad-
vanced stage of disease (HR = 3.26, 95% CI: 0.96–
–7.08, p = 0.05) were significantly associated with
shortening of patients’ survival. However, the pres-
ence of TT genotype of ERCC1 gene did not affect
survival (HR = 1.44, 95% CI: 0.44–4.74, p = 0.55).
Discussion
In NSCLC patients, significant variation in prognosis
and response to treatment was observed regardless
of histopathological diagnosis of cancer. Therefore,
studies on predictive and prognostic molecular mark-
ers are essential in order to improve response rate as
well as to prolong PFS and OS. Expression of ERCC1
is among the most promising prognostic markers for
surgically treated NSCLC patients and predictive
marker for patients receiving platinum-based chemo-
therapy [3].
Zheng et al. showed that high expression of
ERCC1 enzyme in tumor cells was associated with
Table 1B. Characteristics of NSCLC patients and ERCC1 allele frequency
Factors                                                              ERCC1 19007 T>C polymorphism p and c2 value
CC + CT TT
(n = 36, 83.7%) (n = 7, 16.3%)
Gender
Male 29 (80.6%) 4 (57%) 0.394
Female 7 (19.4%) 3 (43%) 0.727
WHO performance status
0 23 (63.9%) 2 (28.6%) 0.189
1 or 2 13 (36.1%) 5 (71.4%) 1.728
Weight loss
Non (< 5%) 18 (50%) 2 (28.6%) 0.531
Yes (≥ 5%) 18 (50%) 5 (71.4%) 0.392
Histological type
Squamous cell carcinoma 19 (52.8%) 6 (85.7%) 0.412
Adenocarcinoma 10 (27.8%) 1 (14.3%) 2.872
Giant cell carcinoma 5 (13.9%) 0 (0%)
NOS 2 (5.5%) 0 (0%)
TNM stage
Locally advanced 21 (58.3%) 2 (28.6%) 0.303
Advanced 15 (41.7%) 5 (71.4%) 1.062
Median PFS (months) 4 0.3 0.03
4.711
Median OS (months) 10.5 1.5 0.084
2.99
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acterized the group of patients with an excellent out-
come after surgical resection [9]. Olaussen et al.
proved that only ERCC1-negative NSCLC patients
benefit significantly from adjuvant chemotherapy [4].
Ceppi et al., in a retrospective study, further validat-
ed concomitant analysis of ERCC1 and RRM1
mRNA level as reliable candidates for personalized
chemotherapy, and showed a higher impact on the
survival of NSCLC patients treated with cisplatin and
gemcitabine [5]. In the first prospective study, Cobo
et al. noted an improvement in the response rate (but
not in PFS or OS) in patients qualified to cisplatin
and docetaxel, or docetaxel and gemcytabine, thera-
py based on ERCC1 mRNA level [10].
The proposed molecular profiles are based on
the analysis of protein expression measured by IHC
method or gene expression (analysis of mRNA level
in real-time PCR technique). Initial material for
such analysis is acquired from the tumor tissue
which is usually difficult to obtain. Polymorphism
of DNA repair genes, which are analyzed in periph-
eral blood leucocytes, have greater clinical signifi-
cance in terms of obtaining samples from lung can-
cer patients.
The literature contains only a limited number of
publications that have assessed the relationship be-
tween polymorphisms of genes encoding DNA repair
proteins and response to treatment based on plati-
num compounds in NSCLC patients.
Here, we observed that uncommon TT genotype
of ERCC1 19007 T>C polymorphism could predict
poor response and shortening of progression free sur-
vival in NSCLC patients treated with platinum-based
I-line chemotherapy. 85.7% of patients with TT gen-
otype demonstrated early progression during first or
second cycle of chemotherapy, in contrast to 36.1%
of C allele carriers with early progression. In conse-
quence of these differences, the median PFS was sig-
nificantly longer, and median OS insignificantly long-
Table 2. Response to platinum-based chemotherapy according to ERCC1 genotype
ERCC1 19007 CR and PR SD PD p and c2 value
T>C polymorphism (n = 19, 44.2%)  (n = 5, 11.6%)  (n = 19, 44.2%)
CC (n = 11) 4 (36.4%) 2 (18.2%) 5 (45.4%) 0.127
CT (n = 25) 14 (56%) 3 (12%) 8 (32%) 7.158
TT (n = 7) 1 (14.3%) 0 6 (85.7%)
CC and CT (n = 36) 18 (50%) 5 (13.9%) 13 (36.1%) 0.052
TT (n = 7) 1 (14.3%) 0 (0%) 6 (85.7%) 5.927
CC and CT (n = 36) 23 (63.9%) 13 (36.1%) 0.045
TT (n = 7) 1 (14.3%) 6 (85.7% 4.009
CC (n = 11) 4 (36.4%) 2 (18.2%) 5 (45.4%) 0.685
CT and TT (n = 32) 15 (46.9%) 3 (9.4%) 14 (43.7%) 0.756
CC (n = 11) 6 (54.5%) 5 (45.6%) 0.8
CT and TT (n = 32) 18 (56.25%) 14 (43.75%) 0.064
Figure 2. Kaplan–Meier curves of PFS probability accor-
ding to the ERCC1 19007 T>C polymorphism
Figure 3. Kaplan–Meier curves of survival probability
according to the ERCC1 19007 T>C polymorphism
good prognosis after surgical treatment of patients in
early stage NSCLC. Co-expression of two proteins —
ERCC1 and RRM1, taking part in DNA repair, char-
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er, among patients with CC or CT genotype than in
patients with TT genotype.
The limitations of our preliminary study are the
small number of analyzed patients and the high per-
centage of patients with poor performance status in
TT genotype group. However, the genetic examina-
tion in our study was performed retrospectively, and
our knowledge about patients’ ERCC1 status was ob-
tained after therapy termination. We speculate that TT
genotype is a poor prognostic factor and that patients
with TT genotype, who had started chemotherapy af-
ter a delay typical for Polish hospitals, are at a worse
clinical stage. Moreover, as was indicated in Tables 1A
and 1B, the differences between the groups with dif-
ferent ERCC1 polymorphisms according to PS status
and advancement of NSCLC are not significant.
In a previous study, Ryu et al. suggested that CC
genotype of ERCC1 19007 T>C polymorphism is
a marker for predicting better survival in NSCLC pa-
tients treated with platinum-based chemotherapy.
However, the authors did not find correlations be-
tween ERCC1 genotype and response to chemother-
apy [11]. Isla et al. showed similar results in advanced
NSCLC patients treated with docetaxel and cisplatin.
In their study, carriers of CC genotype of ERCC1 gene
demonstrated a significantly longer median PFS and
median survival than carriers of CT or TT genotype
without differences in response rate [6].
The study of Kalikaki et al., concerning the poly-
morphisms of genes encoding DNA repair proteins,
had shown that the joint effect of ERCC1 polymor-
phic variants (8092 C>A and 19007 T>C) as well as
the XRCC1 1196 A>G polymorphism were indepen-
dent prognostic factors for OS in advanced NSCLC
patients treated with platinum-based chemotherapy.
The presence of CC genotype and TT genotype of
ERCC1 gene as well as AA genotype of XRCC1 gene
was associated with shorter median survival of analyzed
patients. However, only ERCC1 1907 T>C polymor-
phism significantly predicted response to therapy. CR
or PR was noted in 5.5% of patients with TT genotype
and in 34.7% of patients with CC or CT genotype [12].
A few studies did not find a relationship between
ERCC1 19007 T>C polymorphism and clinical out-
come in advanced NSCLC patients treated with che-
motherapy and surgically resected tumor. Taron et
al. conducted the largest study to date reporting the
effects of ERCC1 polymorphisms (8092 C>A and
19007 T>C) on median survival in 706 Spanish pa-
tients with advanced NSCLC treated with cisplatin and
docetaxel. The uncommon AA genotype at position
8092, but not uncommon TT genotype at position
19007, predicted poor survival in examined patients
[13]. In the study by Tibaldi et al., no significant associ-
ations were found between ERCC1 19007 T>C or XPD
934 G>A and 2251 A>C polymorphisms and either
response or clinical outcome in advanced NSCLC pa-
tients treated with cisplatin and gemcitabine [14]. Pre-
liminary data obtained by Zhou et al. showed that
XRCC3 but not ERCC1 gene polymorphisms might be
a strong predictor of survival in NSCLC patients treat-
ed with cisplatin-based chemotherapy [15]. Moreover,
Takenaka et al. did not observe a relationship between
ERCC1 19007 T>C polymorphism and disease free
survival or overall survival in patients after tumor re-
section due to early stage of NSCLC [7].
In contrast to numerous researchers, we demon-
strated the usefulness of analysis of ERCC1 19007
T>C polymorphism in the prediction of chemother-
apy effect in advanced NSCLC patients. We suggest
that the presence of TT genotype of ERCC1 gene can
predict a worse response for platinum-based chemo-
therapy. Therefore, this study could be a useful tool
in the qualification of advanced NSCLC patients for
appropriate chemotherapy regimen. Moreover, in
patients with poor performance status (PS = 2) and
TT genotype of ERCC1 19007 T>C polymorphisms,
monotherapy with vinorelbine or gemcitabine could
be considered. The analysis of this polymorphism may
provide supplementary data in the routine diagnosis
of NSCLC, especially as it can be easily achieved us-
ing blood samples, and may be easier to adopt in the
clinical setting than tumor gene expression arrays.
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